Opinion

Video

Efficacy and Patient Selection Criteria for PDS with Ranibizumab

Author(s):

Dennis M. Marcus, MD

Video content above is prompted by the following:

  • What are the benefits of using the PDS with ranibizumab, and which patients are ideal candidates for this delivery method?
  • What do we know about the efficacy of the PDS with ranibizumab from the phase 3 ARCHWAY trial?
Related Videos
Insights from Long-Term ASSURE Data for Seladelpar
What Sets Seladelpar Apart From Other PBC Therapies
The Clinical Impact of Seladelpar in PBC Care
Understanding Seladelpar as a Second-Line Treatment for PBC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
HCPLive Gastroenterology Month in Review: November 2024
December 5th 2024

Gastroenterology Month in Review: November 2024

Abigail Brooks, MA
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medical Assistance in Dying

Steven Levine, MD Dominic Sisti, PhD
System Integration: How AI Is Weaving Itself into Neurology
December 5th 2024

System Integration: How AI Is Weaving Itself into Neurology

Marco Meglio
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
Mark Olfson, MD, MPH I Columbia, Department of Psychiatry
December 4th 2024

The Rise of Psychotherapy Largely Benefits Socioeconomically Advantaged Adults

Chelsie Derman
Dexamethasone Raises VTE Risk in Sickle Cell Cases Admitted for COVID-19 | Image Credit: Johns Hopkins University
December 4th 2024

Dexamethasone Raises VTE Risk in COVID-19 Cases with Sickle Cell

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.